Home › Companies › ATEA PHARMACEUTICALS INC. › 2024-2025
Compiled from SEC Form N-PX filings and ATEA PHARMACEUTICALS INC.’s Form 8-K, filed 2025-06-20 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore ATEA PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are ATEA PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-20 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Bruno Lucidi | 46,640,587 | -- | -- | 12,559,084 | 15,781,736 | Majority: yes |
| Elect Director: Polly Murphy, DVM, PhD | 41,184,263 | -- | -- | 18,015,408 | 15,781,736 | Majority: yes |
| Elect Director: Bruce Polsky, MD, MACP, FIDSA | 46,597,653 | -- | -- | 12,602,018 | 15,781,736 | Majority: yes |
| Proposal 2: Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025 | 73,766,274 | 1,192,659 | 22,474 | -- | 0 | Majority: yes |
| Proposal 3: Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers. | 46,450,302 | 12,107,029 | 642,340 | -- | 15,781,736 | Majority: yes |
Source: ATEA PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2025-06-20 — read the filing on EDGAR.
Each item below shows how the 119 asset managers that disclosed a ATEA PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 8 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
ATEA PHARMACEUTICALS INC.’s own tally for this item (“Proposal 3: Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers.”): 46,450,302 for, 12,107,029 against, per its Form 8-K filed 2025-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 85,579,475 outstanding shares: 54.3% for, 14% against (68% of the company cast a for/against vote).
The 118 asset managers below cast 96% of the shares they voted on this item FOR (35,571,511 for, 1,582,747 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,998,464 | 0 | 0 | 0 | For |
| BlackRock | 6,962,391 | 671 | 0 | 0 | For |
| Vanguard | 4,854,649 | 0 | 0 | 0 | For |
| Bain Capital Life Sciences Investors, LLC | 2,485,638 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,932,350 | 0 | 0 | 0 | For |
| State Street | 1,413,826 | 3,213 | 0 | 0 | For |
| Charles Schwab | 1,242,458 | 0 | 0 | 0 | For |
| Renaissance | 1,053,679 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 746,546 | 0 | 0 | Against |
| Newtyn Management, LLC | 580,000 | 0 | 0 | 0 | For |
| Northern Trust | 473,767 | 0 | 0 | 0 | For |
| Two Sigma | 423,858 | 0 | 0 | 0 | For |
| American Century | 0 | 326,186 | 0 | 0 | Against |
| Equitable | 258,013 | 0 | 0 | 0 | For |
| Nuveen | 255,847 | 0 | 0 | 0 | For |
| DE Shaw | 255,554 | 0 | 0 | 0 | For |
| TIAA | 254,249 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 237,800 | 0 | 0 | 0 | For |
| Wellington | 221,694 | 0 | 0 | 0 | For |
| Goldman Sachs | 206,170 | 0 | 0 | 0 | For |
| Dimensional | 156,281 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 147,137 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 143,100 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 0 | 133,300 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 132,546 | 0 | 0 | 0 | For |
Showing the 25 largest of 118 asset managers. See all 118 in the interactive database.
Combines 2 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
ATEA PHARMACEUTICALS INC.’s own tally for this item (“Proposal 2: Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025”): 73,766,274 for, 1,192,659 against, per its Form 8-K filed 2025-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 85,579,475 outstanding shares: 86% for, 1% against (88% of the company cast a for/against vote).
The 43 asset managers below cast 100% of the shares they voted on this item FOR (15,201,067 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,765,568 | 0 | 0 | 0 | For |
| Fidelity | 3,982,987 | 0 | 0 | 0 | For |
| BlackRock | 3,647,018 | 0 | 0 | 0 | For |
| Charles Schwab | 621,155 | 0 | 0 | 0 | For |
| Equitable | 258,013 | 0 | 0 | 0 | For |
| TIAA | 254,249 | 0 | 0 | 0 | For |
| JPMorgan | 181,470 | 0 | 0 | 0 | For |
| American Century | 163,093 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 133,300 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 132,546 | 0 | 0 | 0 | For |
| Goldman Sachs | 131,537 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 90,747 | 0 | 0 | 0 | For |
| Lincoln Financial | 82,675 | 0 | 0 | 0 | For |
| Brighthouse | 70,784 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 70,325 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 70,000 | 0 | 0 | 0 | For |
| Nationwide | 64,479 | 0 | 0 | 0 | For |
| T. Rowe Price | 50,656 | 0 | 0 | 0 | For |
| Global X | 46,292 | 0 | 0 | 0 | For |
| Voya | 44,486 | 0 | 0 | 0 | For |
| Northern Trust | 40,817 | 0 | 0 | 0 | For |
| Pacific Life | 39,227 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 36,183 | 0 | 0 | 0 | For |
| Invesco | 34,510 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 33,201 | 0 | 0 | 0 | For |
Showing the 25 largest of 43 asset managers. See all 43 in the interactive database.
Combines 4 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
ATEA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Bruce Polsky, MD, MACP, FIDSA”): 46,597,653 for, 12,602,018 withheld, per its Form 8-K filed 2025-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 85,579,475 outstanding shares: 54.4% for, 15% withheld (69% of the company cast a for/withheld vote).
The 42 asset managers below cast 100% of the shares they voted on this item FOR (15,048,497 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,765,568 | 0 | 0 | 0 | For |
| Fidelity | 3,982,987 | 0 | 0 | 0 | For |
| BlackRock | 3,647,018 | 0 | 0 | 0 | For |
| Charles Schwab | 621,155 | 0 | 0 | 0 | For |
| Equitable | 138,793 | 0 | 119,220 | 0 | For |
| TIAA | 254,249 | 0 | 0 | 0 | For |
| JPMorgan | 181,470 | 0 | 0 | 0 | For |
| American Century | 163,093 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 133,300 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 132,546 | 0 | 0 | 0 | For |
| Goldman Sachs | 131,537 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 90,747 | 0 | 0 | 0 | For |
| Lincoln Financial | 78,650 | 0 | 4,025 | 0 | For |
| Brighthouse | 70,784 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 70,325 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 70,000 | 0 | 0 | 0 | For |
| Nationwide | 64,479 | 0 | 0 | 0 | For |
| T. Rowe Price | 50,656 | 0 | 0 | 0 | For |
| Global X | 46,292 | 0 | 0 | 0 | For |
| Voya | 44,486 | 0 | 0 | 0 | For |
| Northern Trust | 40,817 | 0 | 0 | 0 | For |
| Pacific Life | 39,227 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 36,183 | 0 | 0 | 0 | For |
| Invesco | 34,510 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 33,201 | 0 | 0 | 0 | For |
Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.
Combines 4 wordings of this item as funds reported it.
79% Majority: yes · of votes cast
ATEA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Bruno Lucidi”): 46,640,587 for, 12,559,084 withheld, per its Form 8-K filed 2025-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 85,579,475 outstanding shares: 54.5% for, 15% withheld (69% of the company cast a for/withheld vote).
The 42 asset managers below cast 100% of the shares they voted on this item FOR (15,048,497 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,765,568 | 0 | 0 | 0 | For |
| Fidelity | 3,982,987 | 0 | 0 | 0 | For |
| BlackRock | 3,647,018 | 0 | 0 | 0 | For |
| Charles Schwab | 621,155 | 0 | 0 | 0 | For |
| Equitable | 138,793 | 0 | 119,220 | 0 | For |
| TIAA | 254,249 | 0 | 0 | 0 | For |
| JPMorgan | 181,470 | 0 | 0 | 0 | For |
| American Century | 163,093 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 133,300 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 132,546 | 0 | 0 | 0 | For |
| Goldman Sachs | 131,537 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 90,747 | 0 | 0 | 0 | For |
| Lincoln Financial | 78,650 | 0 | 4,025 | 0 | For |
| Brighthouse | 70,784 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 70,325 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 70,000 | 0 | 0 | 0 | For |
| Nationwide | 64,479 | 0 | 0 | 0 | For |
| T. Rowe Price | 50,656 | 0 | 0 | 0 | For |
| Global X | 46,292 | 0 | 0 | 0 | For |
| Voya | 44,486 | 0 | 0 | 0 | For |
| Northern Trust | 40,817 | 0 | 0 | 0 | For |
| Pacific Life | 39,227 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 36,183 | 0 | 0 | 0 | For |
| Invesco | 34,510 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 33,201 | 0 | 0 | 0 | For |
Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.
Combines 5 wordings of this item as funds reported it.
70% Majority: yes · of votes cast
ATEA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Polly Murphy, DVM, PhD”): 41,184,263 for, 18,015,408 withheld, per its Form 8-K filed 2025-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 85,579,475 outstanding shares: 48.1% for, 21% withheld (69% of the company cast a for/withheld vote).
The 42 asset managers below cast 100% of the shares they voted on this item FOR (14,073,206 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,765,568 | 0 | 0 | 0 | For |
| Fidelity | 3,979,498 | 0 | 3,489 | 0 | For |
| BlackRock | 3,647,018 | 0 | 0 | 0 | For |
| Charles Schwab | 621,155 | 0 | 0 | 0 | For |
| Equitable | 138,793 | 0 | 119,220 | 0 | For |
| TIAA | 254,249 | 0 | 0 | 0 | For |
| JPMorgan | 181,470 | 0 | 0 | 0 | For |
| American Century | 0 | 0 | 163,093 | 0 | Abstain |
| BRIDGEWAY FUNDS INC | 0 | 0 | 133,300 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 132,546 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 131,537 | 0 | Abstain |
| AIG/SunAmerica | 0 | 0 | 90,747 | 0 | Abstain |
| Lincoln Financial | 78,650 | 0 | 4,025 | 0 | For |
| Brighthouse | 42,429 | 0 | 28,355 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 70,325 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 70,000 | 0 | Abstain |
| Nationwide | 21,608 | 0 | 42,871 | 0 | Abstain |
| T. Rowe Price | 50,656 | 0 | 0 | 0 | For |
| Global X | 0 | 0 | 46,292 | 0 | Abstain |
| Voya | 0 | 0 | 44,486 | 0 | Abstain |
| Northern Trust | 0 | 0 | 40,817 | 0 | Abstain |
| Pacific Life | 39,227 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 36,183 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 34,510 | 0 | Abstain |
| Columbia Threadneedle | 0 | 0 | 33,201 | 0 | Abstain |
Showing the 25 largest of 42 asset managers. See all 42 in the interactive database.
Ranked by the number of ATEA PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 85,579,475 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 11.68% |
| 2 | BlackRock | 8.14% |
| 3 | Vanguard | 5.67% |
| 4 | Bain Capital Life Sciences Investors, LLC | 2.90% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 2.26% |
| 6 | State Street | 1.66% |
| 7 | Charles Schwab | 1.45% |
| 8 | Renaissance | 1.23% |
| 9 | JPMorgan | 0.87% |
| 10 | Newtyn Management, LLC | 0.68% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 10.45% | 13F |
| Jean-Pierre Sommadossi | 10.37% | 13G |
| BML Investment Partners, L.P. | 8.75% | 13G |
| FMR LLC | 7.73% | DEF14A |
| FMR (Fidelity) | 7.03% | 13F |
| JPM Partners LLC | 6.85% | DEF14A |
| Vanguard Group | 5.52% | 13F |
| Radoff Bradley Louis | 3.95% | 13D |
| Geode Capital | 2.31% | 13F |
| State Street | 2.07% | 13F |
Percentages above are of 85,579,475 shares outstanding, as reported by ATEA PHARMACEUTICALS INC. on its Form 10-Q dated 2025-05-09 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ATEA PHARMACEUTICALS INC.’s 10-Q dated 2025-05-09. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At ATEA PHARMACEUTICALS INC.'s shareholder meeting held 2025-06-20, in the 2024-2025 proxy season, 119 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 773 separate fund positions. On the most widely held item on that ballot — APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF THE NAMED EXECUTIVE… — FOR was 79% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ATEA PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-20.
ATEA PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.